CardieX is an ASX listed public company with operations in medical technology, wearable devices, and telehealth.

Our core medical business (AtCor Medical) develops, markets, and distributes medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. Our wearable and “smart device” division (CardieX Labs in partnership with Blumio), develops non-invasive wearable technologies that identify patient risk profiles for hypertension, CVD, and related disorders.

Our telehealth group (inHealth) develops and provides clinically based health coaching and management to health insurance networks, private practice, and medical device companies.

We provide digital and device-based solutions for large-scale population health disorders with significant market scale.

- Current focus is cardiovascular disease (CVD) and heart health – the #1 cause of premature death globally.
- Our long-term future lies in developing large-scale health technologies in other significant global wellness markets (e.g. obesity, orthopedic health, diabetes management, urology).

We provide investment exposure to 3 of the fastest growing global healthcare market opportunities.
INVESTOR FACT SHEET

CORPORATE & FINANCIAL INFORMATION

SECURITIES ON ISSUE:
695,435,563 TOTAL SHARES (ASX.CDX)
97,497,625 TOTAL OPTIONS (ASX.CDX) ($0.05 Ex Price)

STOCK LISTING:
CDX
ASX: AUSTRALIAN SECURITIES EXCHANGE

HEAD OFFICE:
CardieX, Limited
303/15 Lime St
Sydney NSW 2000
Australia

AUDITORS:
BDO

MAJOR STOCK HOLDERS (AS OF MAY, 2019):

<table>
<thead>
<tr>
<th>RANK</th>
<th>NAME</th>
<th>NUMBER OF SHARES</th>
<th>PERCENTAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C2 VENTURES PTY LIMITED</td>
<td>137,616,769</td>
<td>19.79%</td>
</tr>
<tr>
<td>2</td>
<td>MR PAUL COZZI</td>
<td>25,425,114</td>
<td>3.66%</td>
</tr>
<tr>
<td>3</td>
<td>CITICORP NOMINEES PTY LIMITED</td>
<td>16,239,028</td>
<td>2.34%</td>
</tr>
<tr>
<td>4</td>
<td>CB CO PTY LTD</td>
<td>15,470,028</td>
<td>2.22%</td>
</tr>
<tr>
<td>5</td>
<td>MR PAUL JOSEPH COZZI</td>
<td>13,973,617</td>
<td>2.01%</td>
</tr>
<tr>
<td>6</td>
<td>CAMPBELL KITCHENER HUME &amp; ASSOCIATES PTY LTD</td>
<td>11,570,923</td>
<td>1.66%</td>
</tr>
<tr>
<td>7</td>
<td>DRUMNADROCHIT FUTURES PTY LTD</td>
<td>10,068,574</td>
<td>1.45%</td>
</tr>
<tr>
<td>8</td>
<td>MRS JANE GREENSLADE</td>
<td>9,996,504</td>
<td>1.44%</td>
</tr>
<tr>
<td>9</td>
<td>AUSTRALIAN EXECUTOR TRUSTEES LIMITED</td>
<td>8,400,000</td>
<td>1.21%</td>
</tr>
<tr>
<td>10</td>
<td>CPO SUPERANNUATION FUND PTY LTD</td>
<td>7,330,000</td>
<td>1.05%</td>
</tr>
<tr>
<td></td>
<td>Total Top 10</td>
<td>256,090,529</td>
<td>36.8%</td>
</tr>
<tr>
<td></td>
<td>Balance</td>
<td>439,345,034</td>
<td>63.2%</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>695,435,563</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Average Daily Volume (1/7/18 - 24/5/19): 3,178,201
GROUP FINANCIALS

REVENUE:
$4,006,091 FY18
$1,987,846 HY19

CASH:
$2,736,517 FY18
$4,735,364 HY19

C2 VENTURES PTY LTD INVESTMENT TO DATE
$4,000,000 (Niall Cairns & Craig Cooper)

MARKET CAP:
$25,035,680 24/05/19

BOARD OF DIRECTORS

NIALL CAIRNS
Non-Executive Chairman

CRAIG COOPER
Executive Director, CEO, and Managing Director

R. KING NELSON
Non-Executive Director

KEY EXECUTIVES

CRAIG COOPER
Executive Director, CEO, and Managing Director

JARROD WHITE
Chief Financial Officer

ZIHAN LIN
VP of Corporate Development

CHRIS DAX
VP of Operations

DOUG KURSCHINSKI
VP & Global Head of Sales, AtCor Medical

RHONDA WELCH
VP of Global Marketing

LAWRENCE CHAN
Director of Product Development
VALUE PROPOSITION

CardieX has three operating divisions focused on developing and marketing solutions and technologies for large-scale population health disorders.

"Our core mission is to develop a significant and valuable healthcare ecosystem of complementary and strategic products and services - and to provide smarter tools to help identify, diagnose, and treat patients with confidence."

MEDICAL DEVICES
AtCor Medical and its proprietary XCEL system is the world leader in noninvasive measurement of arterial stiffness and central blood pressure (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders.

WEARABLE TECHNOLOGIES
CardieX Labs has a 50/50 joint venture partnership with Silicon Valley-based Blumio, for the development of a radar-based blood pressure sensor incorporating CardieX cBP technology. CardieX is also partnering with leading global wearable and smart device companies to incorporate AtCor’s sensor and diagnostic technology into next generation wearable diagnostic technologies.

TELEHEALTH SOLUTIONS
inHealth Medical Services, is a leading provider of telehealth solutions in the US, providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care program. inHealth’s patient care programs are based on long-term clinical trials that demonstrate superior patient outcomes through the use of telehealth coaching services. inHealth has partnerships with some of the leading healthcare institutions in the USA including Anthem, American Well, and Kaiser Permanente.

Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, wearables, and consumer/digital health.
KEY PARTNERSHIPS

AstraZeneca
Anthem
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
MERCK
Novartis
SunTech Medical

INVESTOR RELATIONS

SHARE REGISTRY
For questions about your shareholding please contact the share registry:
Computershare, Investor Services
Level 3
60 Carrington Street
Sydney NSW 2000
Australia
Tel: +61 2 8234 5000
www.computershare.com/au

GENERAL INVESTOR ENQUIRIES
Jarrod White
Company Secretary
Suite 303, 15 Lime Street
Sydney NSW 2000
Australia
Tel: +61 2 9874 8761
Email: jwhite@cardiex.com

FOR MEDIA & INVESTOR RELATIONS
Peter Taylor
NWR Communications
Tel: +61 412 036 231
Email: peter@nwrcommunications.com.au